SCHEMBL5491971

SCHEMBL5491971

O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](COP(=O)(O)S)O2)cc1F

nearest known ligand 0.74

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
TYMS P04818 4/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5-Fluorodeoxyuridylate SCHEMBL17117772 0.93 LMNA (0.71) LMNASMN1; SMN2TYMS
5-Fluorodeoxyuridylate SCHEMBL6107 0.93 LMNA (0.71) LMNASMN1; SMN2TYMS
5-Fluorodeoxyuridylate SCHEMBL21901970 0.93 LMNA (0.71) LMNASMN1; SMN2TYMS
5-Fluorodeoxyuridylate SCHEMBL15189164 0.93 LMNA (0.71) LMNASMN1; SMN2TYMS
5-Fluorodeoxyuridylate SCHEMBL973436 0.93 LMNA (0.71) LMNASMN1; SMN2TYMS
SCHEMBL13026822 0.90 LMNA (0.67) LMNASMN1; SMN2TYMS
SCHEMBL20428151 0.89 TYMS (0.64) LMNASMN1; SMN2TYMS
SCHEMBL28378385 0.89 LMNA (0.66) LMNASMN1; SMN2TYMS
5-Fluorodeoxyuridylate SCHEMBL25223991 0.88 LMNA (0.69) LMNASMN1; SMN2TYMS
SCHEMBL5491976 0.88 LMNA (0.69) LMNASMN1; SMN2TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262177-B2 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use CELL WORKS THERAPEUTICS, INC. (US) 2007-08-28 US disclosed
US-20050250679-A1 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use Cell Works Therapeutics, Inc., Delaware corporations 2005-11-10 US disclosed
US-6906182-B2 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use CELL WORKS THERAPEUTICS, INC. (US) 2005-06-14 US disclosed
WO-2002043771-A9 CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE CELL WORKS INC (US) 2004-04-29 WO disclosed
EP-1355672-A2 CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE, BIFUNCTIONAL LINKER, AND NUCLEOTIDIC MONOMERS/POLYMERS, AND RELATED COMPOSITIONS AND METHODS OF USE Cell Works Inc. (US) 2003-10-29 EP disclosed
US-20030032584-A1 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use CELL WORKS INC. (US) 2003-02-13 US disclosed
WO-2002043771-A2 CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE CELL WORKS INC. (US) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032584-A1 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use LNPEP, B3GAT3, GALNT1 LMNA 431/4885SMN1; SMN2 3373/4885TYMS 145/4885
US-20050250679-A1 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use LNPEP, B3GAT3, GALNT1 LMNA 449/4885SMN1; SMN2 3310/4885TYMS 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.